Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the NEXUS (R) ...
Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced ...
Endospan, an Israel-based developer of solutions for the endovascular repair of aortic arch disease, announced that the FDA ...
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally ...
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissectionsATLANTA, ...
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 ...
Artivion announces Endospan’s NEXUS Aortic Arch System receives US FDA approval: Atlanta Wednesday, April 8, 2026, 14:00 Hrs [IST] Artivion, Inc., a leading cardiac and vascular ...
Adult structural heart disease is often missed. Early detection and continuous monitoring are vital. Modern treatments like ...
The ACC issued new guidance for managing common pediatric left-to-right shunts, including ASD, VSD, and PDA, in the ...
Research suggests that over 120,000 patients suffer from aortic arch disease in the US and Europe annually, but only around ...
InvestorsHub on MSN
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition
Artivion Inc. (NYSE:AORT) said the U.S. Food and Drug Administration has approved the premarket application for the NEXUS ...
Despite improvements in diagnostic and therapeutic methods and an increased awareness of their clinical significance, abdominal aortic aneurysms (AAAs) continue to be a major source of morbidity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results